Development of a therapeutic vaccine for HSV-2.
A therapeutic vaccine for genital herpes is clearly needed. Vaccines recently developed for HSV-2 in humans have been aimed at eliciting CD4+ T cell responses and neutralizing antibody responses to two HSV-2 glycoproteins (gB and gD). These vaccines have had no therapeutic effect against HSV-2 in human clinical trials. To enable development of an efficacious vaccine, Corixa Corporation has made a major effort to identify novel antigens that can be recognized by human HSV-2-specific CD8+ and CD4+ T cells. Corixa Corporation's proprietary adjuvants and delivery systems, when combined with appropriate antigens, may allow the development of an effective therapeutic vaccine for HSV-2.
Hosken
Nancy A
NA
Corixa Corporation, 1900 9th Avenue, Suite 1100, Seattle, WA 98101, USA. hoskenn@zgi.com
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D000951:Antigens, Neoplasm / Q000008:administration & dosage / Q000302:isolation & purification; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D005260:Female; D006558:Herpes Genitalis / Q000276:immunology / Q000628:therapy*; D018258:Herpesvirus 2, Human / Q000276:immunology*; D006801:Humans; D008297:Male; D014765:Viral Vaccines / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D000951:Antigens, Neoplasm; D014765:Viral Vaccines